In addition, HER2DX was designed specifically for HER2+ early breast cancer and uniquely incorporates an immune-related gene signature, which is particularly relevant in predicting prognosis and response to HER2-targeted therapies15,17,45. This evidence concerns the gene ERBB2 and breast cancer.